GlassScriptPhysician profile
Evelyn E Osakwe
NPI 1619574845
$5,159.75
in general payments reported to CMS, 2019-2025
21 companies · $1,604 in 2025
The $1,604 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $200 · 2022: $295 · 2023: $1,028 · 2024: $2,033 · 2025: $1,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,911 · Education: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,910.55 |
| Education | $753.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,251.10 | 2021-2025 | Carvykti, Darzalex, Tecvayli |
| Astellas Pharma US INC | $699.19 | 2022-2025 | Xospata, Cresemba |
| Celgene Corporation | $533.27 | 2023-2024 | |
| Incyte Corporation | $485.11 | 2023-2025 | Niktimvo, Jakafi, Monjuvi |
| Sobi, INC | $293.51 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $237.84 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $193.21 | 2024 | |
| Janssen Scientific Affairs, LLC | $183.62 | 2023-2024 | Darzalex |
| Beigene USA, INC. | $176.13 | 2023-2024 | Brukinsa |
| Amgen INC. | $172.03 | 2022-2023 | Blincyto |
| Pfizer INC. | $146.25 | 2023-2024 | |
| Abbvie INC. | $113.90 | 2023 | |
| Stemline Therapeutics INC. | $113.14 | 2024 | Elzonris |
| Servier Pharmaceuticals LLC | $112.33 | 2025 | |
| Johnson & Johnson Health Care Systems INC. | $105.43 | 2025 | Carvykti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $100.00 | 2021 | |
| Seagen INC. | $93.00 | 2023 | Adcetris |
| Legend Biotech USA INC. | $85.06 | 2024-2025 | Carvykti |
| Genzyme Corporation | $26.54 | 2024 | |
| Blueprint Medicines Corporation | $25.00 | 2025 | Ayvakit |
| Pharmacyclics LLC, An Abbvie Company | $14.09 | 2023 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evelyn Osakwe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.